Literature DB >> 24647830

Immediate neurological recovery following perispinal etanercept years after brain injury.

Edward Tobinick1, Helen Rodriguez-Romanacce, Arthur Levine, Tracey A Ignatowski, Robert N Spengler.   

Abstract

Positron emission tomographic brain imaging and pathological examination have revealed that a chronic, intracerebral neuroinflammatory response lasting for years after a single brain injury may occur in humans. Evidence suggests the immune signaling molecule, tumor necrosis factor (TNF), is centrally involved in this pathology through its modulation of microglial activation, role in synaptic dysfunction, and induction of depressive symptoms and neuropathic pain. Etanercept is a recombinant TNF receptor fusion protein and potent TNF inhibitor that has been found to reduce microglial activation and neuropathic pain in multiple experimental models. We report that a single dose of perispinal etanercept produced an immediate, profound, and sustained improvement in expressive aphasia, speech apraxia, and left hemiparesis in a patient with chronic, intractable, debilitating neurological dysfunction present for more than 3 years after acute brain injury. These results indicate that acute brain injury-induced pathologic levels of TNF may provide a therapeutic target that can be addressed years after injury. Perispinal administration of etanercept is capable of producing immediate relief from brain injury-mediated neurological dysfunction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24647830     DOI: 10.1007/s40261-014-0186-1

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  41 in total

Review 1.  Perispinal etanercept: a new therapeutic paradigm in neurology.

Authors:  Edward Tobinick
Journal:  Expert Rev Neurother       Date:  2010-06       Impact factor: 4.618

Review 2.  The role of inflammation in epilepsy.

Authors:  Annamaria Vezzani; Jacqueline French; Tamas Bartfai; Tallie Z Baram
Journal:  Nat Rev Neurol       Date:  2010-12-07       Impact factor: 42.937

Review 3.  The cerebrospinal venous system: anatomy, physiology, and clinical implications.

Authors:  Edward Tobinick; Charles P Vega
Journal:  MedGenMed       Date:  2006-02-22

4.  Epilepsy and inflammation in the brain: overview and pathophysiology.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2014-01       Impact factor: 7.500

Review 5.  Documentation of off-label use of biologics in Rheumatoid Arthritis.

Authors:  Daniel E Furst; Roy Fleischman; Joachim Kalden; Arthur Kavanaugh; Joachim Sieper; Philip Mease; Josef Smolen; Ferrie Breedveld
Journal:  Ann Rheum Dis       Date:  2013-04       Impact factor: 19.103

6.  The Rivermead Post Concussion Symptoms Questionnaire: a measure of symptoms commonly experienced after head injury and its reliability.

Authors:  N S King; S Crawford; F J Wenden; N E Moss; D T Wade
Journal:  J Neurol       Date:  1995-09       Impact factor: 4.849

7.  Accuracy of the Jamar dynamometer.

Authors:  R Härkönen; R Harju; H Alaranta
Journal:  J Hand Ther       Date:  1993 Oct-Dec       Impact factor: 1.950

Review 8.  Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease.

Authors:  Edward Tobinick
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

9.  Simple foot tapping test as a quantitative objective assessment of cervical myelopathy.

Authors:  Takuya Numasawa; Atsushi Ono; Kanichiro Wada; Yoshihito Yamasaki; Toru Yokoyama; Shuichi Aburakawa; Kazunari Takeuchi; Gentaro Kumagai; Hitoshi Kudo; Takashi Umeda; Shigeyuki Nakaji; Satoshi Toh
Journal:  Spine (Phila Pa 1976)       Date:  2012-01-15       Impact factor: 3.468

Review 10.  The ethics of clinical innovation in psychopharmacology: Challenging traditional bioethics.

Authors:  S Nassir Ghaemi; Frederick K Goodwin
Journal:  Philos Ethics Humanit Med       Date:  2007-11-08       Impact factor: 2.464

View more
  20 in total

Review 1.  Practice advisory: Etanercept for poststroke disability: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Gary S Gronseth; Steven R Messé
Journal:  Neurology       Date:  2016-06-07       Impact factor: 9.910

2.  Prophylactic etanercept treatment in cisplatin ototoxicity.

Authors:  Sinem Dasli; Murat Topdag; Ahmet Mutlu; Ahmet Kara; Murat Ozturk
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-20       Impact factor: 2.503

3.  Inhibition of Peripheral TNF-α and Downregulation of Microglial Activation by Alpha-Lipoic Acid and Etanercept Protect Rat Brain Against Ischemic Stroke.

Authors:  Ming-Hsiu Wu; Chao-Ching Huang; Chung-Ching Chio; Kuen-Jer Tsai; Ching-Ping Chang; Nan-Kai Lin; Mao-Tsun Lin
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

Review 4.  Role of innate inflammation in traumatic brain injury.

Authors:  Sandrine Bourgeois-Tardif; Louis De Beaumont; José Carlos Rivera; Sylvain Chemtob; Alexander G Weil
Journal:  Neurol Sci       Date:  2021-01-19       Impact factor: 3.307

5.  Chronic constriction injury-induced nociception is relieved by nanomedicine-mediated decrease of rat hippocampal tumor necrosis factor.

Authors:  Elizabeth Gerard; Robert N Spengler; Adela C Bonoiu; Supriya D Mahajan; Bruce A Davidson; Hong Ding; Rajiv Kumar; Paras N Prasad; Paul R Knight; Tracey A Ignatowski
Journal:  Pain       Date:  2015-07       Impact factor: 7.926

6.  Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.

Authors:  Tracey A Ignatowski; Robert N Spengler; Krishnan M Dhandapani; Hedy Folkersma; Roger F Butterworth; Edward Tobinick
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

7.  Authors' reply to Whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.

Authors:  Tracey A Ignatowski; Robert N Spengler; Edward Tobinick
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 8.  Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date.

Authors:  Antonino Tuttolomondo; Rosaria Pecoraro; Antonio Pinto
Journal:  Drug Des Devel Ther       Date:  2014-11-07       Impact factor: 4.162

Review 9.  Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents.

Authors:  Ian A Clark; Bryce Vissel
Journal:  J Neuroinflammation       Date:  2016-09-05       Impact factor: 8.322

Review 10.  A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease.

Authors:  Ian A Clark; Bryce Vissel
Journal:  Neural Plast       Date:  2015-07-22       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.